141 related articles for article (PubMed ID: 9387043)
1. Discovery of cryptophycin-1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in mice.
Corbett TH; Valeriote FA; Demchik L; Lowichik N; Polin L; Panchapor C; Pugh S; White K; Kushner J; Rake J; Wentland M; Golakoti T; Hetzel C; Ogino J; Patterson G; Moore R
Invest New Drugs; 1997; 15(3):207-18. PubMed ID: 9387043
[TBL] [Abstract][Full Text] [Related]
2. Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors.
Liang J; Moore RE; Moher ED; Munroe JE; Al-awar RS; Hay DA; Varie DL; Zhang TY; Aikins JA; Martinelli MJ; Shih C; Ray JE; Gibson LL; Vasudevan V; Polin L; White K; Kushner J; Simpson C; Pugh S; Corbett TH
Invest New Drugs; 2005 Jun; 23(3):213-24. PubMed ID: 15868377
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of cryptophycin analogs with substitution at C-6 (fragment C region).
Varie DL; Shih C; Hay DA; Andis SL; Corbett TH; Gossett LS; Janisse SK; Martinelli MJ; Moher ED; Schultz RM; Toth JE
Bioorg Med Chem Lett; 1999 Feb; 9(3):369-74. PubMed ID: 10091686
[TBL] [Abstract][Full Text] [Related]
4. First generation design, synthesis, and evaluation of azepine-based cryptophycin analogues.
Smith AB; Cho YS; Zawacki LE; Hirschmann R; Pettit GR
Org Lett; 2001 Dec; 3(25):4063-6. PubMed ID: 11735585
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of novel cryptophycin analogs with modification in the beta-alanine region.
Shih C; Gossett LS; Gruber JM; Grossman CS; Andis SL; Schultz RM; Worzalla JF; Corbett TH; Metz JT
Bioorg Med Chem Lett; 1999 Jan; 9(1):69-74. PubMed ID: 9990459
[TBL] [Abstract][Full Text] [Related]
6. Preclinical anticancer activity of cryptophycin-8.
Corbett TH; Valeriote FA; Demchik L; Polin L; Panchapor C; Pugh S; White K; Knight J; Jones J; Jones L; LoRusso P; Foster B; Wiegand RA; Lisow L; Golakoti T; Heltzel CE; Ogino J; Patterson GM; Moore RE
J Exp Ther Oncol; 1996 Mar; 1(2):95-108. PubMed ID: 9414393
[TBL] [Abstract][Full Text] [Related]
7. In vitro bioassays for anticancer drug screening: effects of cell concentration and other assay parameters on growth inhibitory activity.
Lieberman MM; Patterson GM; Moore RE
Cancer Lett; 2001 Nov; 173(1):21-9. PubMed ID: 11578805
[TBL] [Abstract][Full Text] [Related]
8. Cryptophycin 1 cellular levels and effects in vitro using L1210 cells.
Foster BJ; Fortuna M; Media J; Wiegand RA; Valeriote FA
Invest New Drugs; 1998-1999; 16(3):199-204. PubMed ID: 10360599
[TBL] [Abstract][Full Text] [Related]
9. Total synthesis and anti-tubulin activity of epi-c3 analogues of cryptophycin-24.
Buck SB; Huff JK; Himes RH; Georg GI
J Med Chem; 2004 Jul; 47(14):3697-9. PubMed ID: 15214797
[TBL] [Abstract][Full Text] [Related]
10. Cryptophycin: a new antimicrotubule agent active against drug-resistant cells.
Smith CD; Zhang X; Mooberry SL; Patterson GM; Moore RE
Cancer Res; 1994 Jul; 54(14):3779-84. PubMed ID: 7913408
[TBL] [Abstract][Full Text] [Related]
11. A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment a epoxides and chlorohydrins.
Al-Awar RS; Ray JE; Schultz RM; Andis SL; Kennedy JH; Moore RE; Liang J; Golakoti T; Subbaraju GV; Corbett TH
J Med Chem; 2003 Jul; 46(14):2985-3007. PubMed ID: 12825938
[TBL] [Abstract][Full Text] [Related]
12. Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides.
Shih C; Teicher BA
Curr Pharm Des; 2001 Sep; 7(13):1259-76. PubMed ID: 11472266
[TBL] [Abstract][Full Text] [Related]
13. Aplidin increases sensitivity to treatment in leukemia and lymphoma cells.
Expert Rev Anticancer Ther; 2003 Apr; 3(2):133-4. PubMed ID: 12722872
[No Abstract] [Full Text] [Related]
14. Halohydrin analogues of cryptophycin 1: synthesis and biological activity.
Georg GI; Ali SM; Stella VJ; Waugh WN; Himes RH
Bioorg Med Chem Lett; 1998 Aug; 8(15):1959-62. PubMed ID: 9873466
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1.
Panda D; Himes RH; Moore RE; Wilson L; Jordan MA
Biochemistry; 1997 Oct; 36(42):12948-53. PubMed ID: 9335554
[TBL] [Abstract][Full Text] [Related]
16. In vitro cytotoxicity against fresh human tumors and P388 leukemia predicts the differential in vivo activity of a series of anthracene anticancer drugs.
Alberts DS; Dorr RT; Wunz TP; Remers WA; Einspahr J; Liu R; Salmon SE
Anticancer Drugs; 1991 Feb; 2(1):69-77. PubMed ID: 1958855
[TBL] [Abstract][Full Text] [Related]
17. Cryptophycin affinity labels: synthesis and biological activity of a benzophenone analogue of cryptophycin-24.
Vidya R; Eggen M; Georg GI; Himes RH
Bioorg Med Chem Lett; 2003 Feb; 13(4):757-60. PubMed ID: 12639575
[TBL] [Abstract][Full Text] [Related]
18. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines.
Wagner MM; Paul DC; Shih C; Jordan MA; Wilson L; Williams DC
Cancer Chemother Pharmacol; 1999; 43(2):115-25. PubMed ID: 9923816
[TBL] [Abstract][Full Text] [Related]
19. Induction of apoptosis by cryptophycin 1, a new antimicrotubule agent.
Mooberry SL; Busquets L; Tien G
Int J Cancer; 1997 Nov; 73(3):440-8. PubMed ID: 9359493
[TBL] [Abstract][Full Text] [Related]
20. Total synthesis and antitubulin activity of c10 analogues of cryptophycin-24.
Buck SB; Huff JK; Himes RH; Georg GI
J Med Chem; 2004 Jan; 47(3):696-702. PubMed ID: 14736249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
